Cargando…
Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy
BACKGROUND: Hepatitis C virus (HCV) infection is common worldwide. The treatment typically involves a combination of interferon-alpha (IFN-α) and ribavirin (RBV) therapy; however, the use of IFN-α is well documented to be associated with thyroid disease, the most common autoimmune disorder associate...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108099/ https://www.ncbi.nlm.nih.gov/pubmed/27857890 http://dx.doi.org/10.4103/2229-516X.192587 |
_version_ | 1782467304822407168 |
---|---|
author | Goyal, Gitanjali Panag, KMDS Garg, Ravinder |
author_facet | Goyal, Gitanjali Panag, KMDS Garg, Ravinder |
author_sort | Goyal, Gitanjali |
collection | PubMed |
description | BACKGROUND: Hepatitis C virus (HCV) infection is common worldwide. The treatment typically involves a combination of interferon-alpha (IFN-α) and ribavirin (RBV) therapy; however, the use of IFN-α is well documented to be associated with thyroid disease, the most common autoimmune disorder associated with IFN-α. AIM: The aim of the present study was to know the prevalence of thyroid abnormality in the HCV-positive patients on IFN and antiviral therapy. MATERIALS AND METHODS: Fifty known HCV positive patients were enrolled for the study. All the patients were on IFN (3 million unit subcutaneously 3 times/week) and antiviral therapy (oral RBV 1000–1200 mg/day). Thyroid function tests were performed first at the start of treatment and then after 12 weeks of treatment. RESULTS: 13 (26%) of the patients were found to develop hypothyroidism, and 1 (2%) patient developed hyperthyroidism in the course of 12 weeks therapy. CONCLUSION: HCV patients on IFN and antiviral therapy have an effect on the thyroid gland, so these patients should be regularly screened for thyroid disorders and appropriately treated to maintain euthyroid status. |
format | Online Article Text |
id | pubmed-5108099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-51080992016-11-17 Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy Goyal, Gitanjali Panag, KMDS Garg, Ravinder Int J Appl Basic Med Res Original Article BACKGROUND: Hepatitis C virus (HCV) infection is common worldwide. The treatment typically involves a combination of interferon-alpha (IFN-α) and ribavirin (RBV) therapy; however, the use of IFN-α is well documented to be associated with thyroid disease, the most common autoimmune disorder associated with IFN-α. AIM: The aim of the present study was to know the prevalence of thyroid abnormality in the HCV-positive patients on IFN and antiviral therapy. MATERIALS AND METHODS: Fifty known HCV positive patients were enrolled for the study. All the patients were on IFN (3 million unit subcutaneously 3 times/week) and antiviral therapy (oral RBV 1000–1200 mg/day). Thyroid function tests were performed first at the start of treatment and then after 12 weeks of treatment. RESULTS: 13 (26%) of the patients were found to develop hypothyroidism, and 1 (2%) patient developed hyperthyroidism in the course of 12 weeks therapy. CONCLUSION: HCV patients on IFN and antiviral therapy have an effect on the thyroid gland, so these patients should be regularly screened for thyroid disorders and appropriately treated to maintain euthyroid status. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC5108099/ /pubmed/27857890 http://dx.doi.org/10.4103/2229-516X.192587 Text en Copyright: © 2016 International Journal of Applied and Basic Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Goyal, Gitanjali Panag, KMDS Garg, Ravinder Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy |
title | Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy |
title_full | Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy |
title_fullStr | Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy |
title_full_unstemmed | Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy |
title_short | Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy |
title_sort | prevalence of thyroid disorders in hepatitis c virus positive patients on interferon and antiviral therapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108099/ https://www.ncbi.nlm.nih.gov/pubmed/27857890 http://dx.doi.org/10.4103/2229-516X.192587 |
work_keys_str_mv | AT goyalgitanjali prevalenceofthyroiddisordersinhepatitiscviruspositivepatientsoninterferonandantiviraltherapy AT panagkmds prevalenceofthyroiddisordersinhepatitiscviruspositivepatientsoninterferonandantiviraltherapy AT gargravinder prevalenceofthyroiddisordersinhepatitiscviruspositivepatientsoninterferonandantiviraltherapy |